5'-Fluoroindirubinoxime

  Cat. No.:  DC28163   Featured
Chemical Structure
861214-33-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM.
Cas No.: 861214-33-7
SMILES: C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=C(C=C4)F)O)N=O
Formula: C16H10FN3O2
M.Wt: 295.27
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: 5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM[1].
Target: 15 nM (FLT3)[1].
In Vivo: 5'-Fluoroindirubinoxime (5’-FIO, 10 μmol/L/100 μL (~2.95 mg/mL) every other day beginning on day 6, S.C..) exhibits significant anti-tumor activity in rats[2]. Animal Model: Rat tumor model based RK3E-ras cells[2]. Dosage: S.C.. Administration: 10 μmol/L/100 μL (~2.95 mg/mL) every other day beginning on day 6. Result: Effectively inhibited tumor growth.
In Vitro: 5'-Fluoroindirubinoxime (5’-FIO, compound 13) exhibits IC50 values of 1.53 μM and 1.27 μM for VEGFR2 and Aurora A, respectively[1]. 5'-Fluoroindirubinoxime (5’-FIO) exhibits IC50 values of 12.2 μM, 2.1 μM, 3.4 μM and 5.1 μM in A549, SNU-638, HT-1080 and RK3E-ras cancer cells, respectively. 5'-Fluoroindirubinoxime (5’-FIO) induces the apoptosis in RK3E-ras cells[2].
References: [1]. Choi SJ, et al. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7. [2]. Kim SA, et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007 Jan 1;13(1):253-9.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC49069 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).
DC48999 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).
DC48860 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).
DC44219 FLT3-IN-3 FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.
DC28163 5'-Fluoroindirubinoxime 5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM.
DC10921 ATH686 ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase.
X